CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer

References

• Bellmunt J, Albiol S, Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.19(Suppl. 2), II47–II48 (2008).
   PubMedGoogle Scholar
• Montie JE, Clark PE, Eisenberger MA et al. Bladder cancer. J. Natl Compr. Canc. Netw.7(1), 8–39 (2009).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Palapattu GS et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol.176(6 Pt 1), 2414–2422; discussion 2422 (2006).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol.48(2), 189–199; discussion 199–201 (2005).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48(2), 202–205; discussion 205–206 (2005).
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet353(9165), 1689–1694 (1999).
   PubMed Web of Science ®Google Scholar
• Joudi FN, Smith BJ, O’Donnell MA; National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter Phase II trial of combination bacillus Calmette–Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol. Oncol.24(4), 344–348 (2006).
   PubMed Web of Science ®Google Scholar
• Herr HW, Morales A. History of bacillus Calmette–Guérin and bladder cancer: an immunotherapy success story. J. Urol.179(1), 53–56 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenbaum RS, Park MC, Fleischmann J. Intravesical bacille Calmette–Guérin therapy for muscle invasive bladder cancer. Urology47(2), 208–211 (1996).
   PubMedGoogle Scholar
• Volkmer BG, Gschwend JE, Maier SH, Seidl-Schlick EM, Bach D, Romics I. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette–Guérin. J. Urol.169(3), 931–934; discussion 934–935 (2003).
   PubMedGoogle Scholar
• Eguchi J, Hiroishi K, Ishii S, Mitamura K. Interferon-α and interleukin-12 gene therapy of cancer: interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol. Immunother.52(6), 378–386 (2003).
   PubMed Web of Science ®Google Scholar
• Iles RK. Ectopic hCG-β expression by epithelial cancer: malignant behavior, metastasis and inhibition of tumor cell apoptosis. Mol. Cell Endocrinol.2, 264–270 (2007).
   Google Scholar
• Dangles V, Halberstam I, Scardino A et al. Tumor-associated antigen human chorionic gonadotropin β contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes. Cancer Immunol. Immunother.50(12), 673–681 (2002).
   PubMedGoogle Scholar
• Hotakainen K, Lintula S, Jarvinen R et al. Overexpression of human chorionic gonadotropin β genes 3, 5 and 8 in tumor tissue and urinary cells of bladder cancer patients. Tumour Biol.28(1), 52–56 (2007).
   PubMedGoogle Scholar
• Lazar V, Diez SG, Laurent A et al. Expression of human chorionic gonadotropin β subunit genes in superficial and invasive bladder carcinomas. Cancer Res.55(17), 3735–3738 (1995).
   PubMed Web of Science ®Google Scholar
• Ozkardes H, Ergen A, Ozen HA, Ayhan A, Remzi D. Immunohistochemical detection of β-human chorionic gonadotropin in urothelial carcinoma. Int. Urol. Nephrol.23(1), 5–11 (1991).
   PubMedGoogle Scholar
• Smeets W, Pauwels R, Schapers R. Serum free β-hCG, a biomarker for bladder carcinoma patients?. Int. J. Biol. Markers.12(2), 83–84 (1997).
   PubMedGoogle Scholar
• Dirnhofer S, Koessler P, Ensinger C, Feichtinger H, Madersbacher S, Berger P. Production of trophoblastic hormones by transitional cell carcinoma of the bladder: association to tumor stage and grade. Hum. Pathol.29(4), 377–382 (1998).
   PubMed Web of Science ®Google Scholar
• Nishimura R, Koizumi T, Morisue K et al. Expression and secretion of the β subunit of human chorionic gonadotropin by bladder carcinoma in vivo and in vitro. Cancer Res.55(7), 1479–1484 (1995).
   PubMedGoogle Scholar
• Hotakainen K, Ljungberg B, Paju A, Rasmuson T, Alfthan H, Stenman UH. The free β subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br. J. Cancer86, 185–189 (2002).
   PubMed Web of Science ®Google Scholar
• Lundin M, Nordling S, Lundin J, Alfthan H, Stenman UH, Haglund C. Tissue expression of human chorionic gonadotropin β predicts outcome in colorectal cancer: a comparison with serum expression. Int. J. Cancer95, 18–22 (2001).
   PubMedGoogle Scholar
• Louhimo J, Alfthan H, Stenman UH, Haglund C. Serum HCG β and CA72–74 are stronger prognostic factors than CEA, CA19–19 and CA242 in pancreatic cancer. Oncology66(2), 126–131 (2004).
   PubMedGoogle Scholar
• Marcillac I, Troalen F, Bidart JM et al. Free human chorionic gonadotropin β subunit in gonadal and nongonadal neoplasms. Cancer Res.52(14), 3901–3907 (1992).
   PubMed Web of Science ®Google Scholar
• Iles RK, Persad R, Trivedi M et al. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br. J. Urol.77(1), 61–69 (1996).
   PubMedGoogle Scholar
• Gillott DJ, Iles RK, Chard T. The effects of β-human chorionic gonadotrophin on the in vitro growth of bladder cancer cell lines. Br. J. Cancer73(3), 323–326 (1996).
   PubMedGoogle Scholar
• Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free β subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br. J. Cancer82(9), 1553–1556 (2000).
   PubMedGoogle Scholar
• Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol.11(9), 861–870 (2010).
   PubMed Web of Science ®Google Scholar
• Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar AG. Recent advances in contraceptive vaccine development: a mini-review. Hum. Reprod.20(12), 3271–3283 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens VC. Use of synthetic peptides as immunogens for developing a vaccine against human chorionic gonadotropin. Ciba Found. Symp.119, 200–225 (1986).
   PubMedGoogle Scholar
• Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a β-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res.8(7), 2044–2051 (2002).
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr. Mol. Med.1(4), 469–474 (2001).
   PubMedGoogle Scholar
• Engering AJ, Cella M, Fluitsma D et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol.27(9), 2417–2425 (1997).
   PubMed Web of Science ®Google Scholar
• Lees CJ, Apostolopoulos V, Acres B et al. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine19(2–3), 158–162 (2000).
   PubMed Web of Science ®Google Scholar
• He LZ, Crocker A, Lee J, Mendoza-Ramirez J et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J. Immunol.178, 6259–6267 (2007).
   PubMed Web of Science ®Google Scholar
• He LZ, Ramakrishna V, Connolly JE et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin β. Clin. Cancer Res.10(6), 1920–1927 (2004).
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Vasilakos JP, Tario JD Jr, Berger MA, Wallace PK, Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J. Transl. Med.5, 5 (2007).
   PubMed Web of Science ®Google Scholar
• Morse M, Chapman R, Powderly J et al. Phase I clinical results of an APC-targeted hCG-β vaccine (CDX-1307) with TLR agonists. J. Clin. Oncol.27(15 Suppl.), (2009) (Abstract 3006).
   Google Scholar
• Bradley DA, Morse M, Keler T et al. A randomized Phase II study of a novel antigen-presenting cell-targeted hCG-β vaccine (the CDX-1307 regimen) in muscle-invasive bladder cancer. J. Clin. Oncol.28(15 Suppl.), (2010) (Abstract TPS228).
   Google Scholar
• Morse MA, Chapman R, Powderly J et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self antigens in cancer patients. Clin. Cancer Res. DOI: 10.1158/1078-0432.CCR-11-0891 (2011) (Epub ahead of print).
   Google Scholar
• Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res.65(18), 8059–8064 (2005).
   PubMed Web of Science ®Google Scholar
• Jähnisch H, Füssel S, Kiessling A et al. Dendritic cell-based immunotherapy for prostate cancer. Clin. Dev. Immunol.2010, 517493 (2010).
   PubMedGoogle Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Keler T, Ramakrishna V, Fanger MW. Mannose receptor-targeted vaccines. Expert Opin. Biol. Ther.4(12), 1953–1962 (2004).
   PubMed Web of Science ®Google Scholar
• Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol.24(5), 571–578 (2004).
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Kärre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today11(7), 237–244 (1990).
   PubMedGoogle Scholar
• Peng G, Guo Z, Kiniwa Y et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science309(5739), 1380–1384 (2005).
   PubMed Web of Science ®Google Scholar